Abbott Laboratories's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Abbott Laboratories (ABT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Abbott Laboratories vs Its Competitors
- TTM: Trailing 12-month revenue of 46,585M vs 850,100M combined for its competitors (5.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+8.1% annualized vs trailing 12 months), vs accelerating (+2.6%) for its tracked peer group.
- Growth: Abbott Laboratories generated 13.0% revenue growth year over year in Q2 2026, vs 9.4% for its competitors combined.
- Profitability: Its 7.4% net margin compares with 9.0% for the peer group.
- Scale: Abbott Laboratories ranks #7 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 3.4% of industry market cap.
- Peer revenue share: Abbott Laboratories accounted for 5.5% of combined revenue among its tracked peer group, up from 5.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.41M compares with $0.70M for the peer group (0.6x).
- Structure: Abbott Laboratories operates in the following segments: Diabetes Care, Core Laboratory, Adult Nutritionals, Key Emerging Markets, Pediatric Nutritionals, Cancer Diagnostics, Rapid and Molecular, Electrophysiology, Vascular, Rhythm Management, Structural Heart, Other Emerging Markets, Heart Failure, Neuromodulation, Corporate and Unallocated.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ABT Sales vs. its Competitors, Q2 2026
Abbott Laboratories reported revenue growth of 13.02 % year on year in Q2 2026, above its competitors' combined revenue growth of 9.40 %.
With a net margin of 7.37 %, Abbott Laboratories reported lower profitability than its competitors (9.02 %).
Abbott Laboratories generated 5.46 % of the combined sales of its peer group, up from 5.29 % a year earlier.
Abbott Laboratories vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Abbott Laboratories reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Abbott Laboratories and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Abbott Laboratories | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (26) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Abbott Laboratories's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 13.0% for Abbott Laboratories. Abbott Laboratories's share of combined industry revenue moved from 2.32% to 2.41%, a gain of 0.09 percentage points.
Abbott Laboratories's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Abbott Laboratories | Yes | Yes | No | No |
| Competitors combined (128) | ||||
| High-Confidence Competitors (38) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ABT Stock Performance relative to its Competitors
ABT Stock Performance relative to High-Confidence Competitors
ABT Stock Performance relative to Similar-Size Competitors
ABT Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Rockwell Medical inc | 282.9% | Outperformed |
| 3 | Atyr Pharma Inc | 282.9% | Outperformed |
| 4 | Elite Health Systems Inc | 282.9% | Outperformed |
| 5 | Damora Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Abbott Laboratories's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Abbott Laboratories's Comment on Competition and Industry Peers
Publicly Traded Peers of Abbott Laboratories
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Abbott Laboratories |
202,028.93 | 46,585.00 |
 Eli Lilly And Company |
1,280,483.42 | 86,462.00 |
 Johnson and Johnson |
683,404.26 | 99,335.00 |
 Abbvie Inc |
528,942.00 | 66,014.00 |
 Merck and Co Inc |
375,020.59 | 66,569.00 |
 Novartis Ag |
320,541.80 | 56,674.00 |
| SUBTOTAL | 6,168,681.34 | 1,109,107.79 |
Sign in to see all competitors of Abbott Laboratories.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Abbott Laboratories versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Abbott Laboratories's Competitors Named by the Company
Competitive relationships identified from Abbott Laboratories reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Neuroone Medical Technologies Corp | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Pulse Biosciences Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Edwards Lifesciences Corporation | Company report | 85% |
| Inspiremd Inc | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Orchestra Biomed Holdings Inc | Company report | 85% |
| Senseonics Holdings Inc | Company report | 85% |
| Movano Inc | Company report | 85% |
| Acutus Medical Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
| Co diagnostics Inc | Company report | 85% |
| Usbc Inc | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Manhattan Scientifics Inc | Company report | 85% |
| Avinger Inc | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Lemaitre Vascular Inc | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Minimed Group Inc | Company report | 85% |
| Northview Acquisition Corp | Company report | 85% |
| Starco Brands Inc | Company report | 85% |
| Artivion Inc | Company report | 85% |
| Glucotrack Inc | Company report | 85% |
| Virax Biolabs Group Limited | Company report | 85% |
| KNW | Company report | 85% |
| Nevro Corp | Company report | 85% |
| Cannaisseur Group Inc. | Company report | 85% |
| BSGM | Company report | 85% |
| AWH | Company report | 85% |
| Silk Road Medical Inc | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Aspira Women s Health inc | Company report | 85% |
| Avanos Medical Inc | Company report | 85% |
| Codexis inc | Company report | 85% |
| Nemaura Medical Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Diagnostic Products | Company report | 85% |
| Nutritional Products | Company report | 85% |
| Dexcom Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Medicines Co | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Biostax Corp | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Orasure Technologies Inc | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Alcon inc | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
| Irhythm Holdings Inc | Company report | 85% |
| Taro Pharmaceutical Industries Ltd | Company report | 85% |
| Cvrx inc | Company report | 85% |
| Tandem Diabetes Care Inc | Company report | 85% |
| Vivani Medical Inc | Company report | 85% |
| Solana Company | Company report | 85% |
| Medtronic Plc | Company report | 85% |
| American Bio Medica Corporation | Company report | 85% |
| Cardiovascular Systems Inc | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Non Invasive Monitoring Systems Inc | Company report | 85% |
| Masimo Corp | Company report | 85% |
| Semler Scientific inc | Company report | 85% |
| Neuropace Inc | Company report | 85% |
| Stereotaxis Inc | Company report | 85% |
| Baxter International Inc | Company report | 85% |
| Autonomix Medical Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Surmodics Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Neurometrix Inc | Company report | 85% |
| Biomerica Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Modular Medical Inc | Company report | 85% |
| Embecta Corp | Company report | 85% |
| Owlet Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Organon and Co | Company report | 85% |
| Adagio Medical Holdings inc | Company report | 85% |
| Insulet Corporation | Company report | 85% |
| Escalon Medical Corp | Company report | 85% |
| Heartsciences Inc | Company report | 85% |
| Thermo Fisher Scientific Inc | Company report | 85% |
| Intelligent Bio Solutions Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Point Of Care Nano technology Inc | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Takeda Pharmaceutical Company Limited | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Meihua International Medical Technologies Co Ltd | Company report | 85% |
| Hologic Inc | Company report | 85% |
| Guided Therapeutics Inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Axonics Inc | Company report | 85% |
| Elite Health Systems Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Universal Biosensors Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Abbott Laboratories's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Abbott Laboratories's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Thermo Fisher Scientific Inc | Clinical Research 20.15 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Abbott Laboratories.
Abbott Laboratories's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Abbott Laboratories | 202,029 | 405,087 | 47,174 |
| Eli Lilly And Company | 1,280,483 | 1,729,240 | 551,594 |
| Johnson and Johnson | 683,404 | 705,504 | 114,311 |
| Abbvie Inc | 528,942 | 1,158,140 | 181,509 |
| Merck and Co Inc | 375,021 | 887,587 | 42,267 |
| Novartis Ag | 320,542 | 752,973 | 185,566 |
| PEERS TOTAL | 5,966,652 | 698,748 | 90,558 |
Sign in to see all peers for Abbott Laboratories.
Abbott Laboratories's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 57.70 % |
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Thermo Fisher Scientific Inc | North America 51.63 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Abbott Laboratories.
Abbott Laboratories's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Abbott Laboratories's industry classification, broader than the peer set above. Market cap in millions of $.Abbott Laboratories ranks #7 of 496 companies by market capitalization in its industry, holding 3.39 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 202,029 | 3.39 % |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
Market cap and industry share for the rest of Abbott Laboratories's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Abbott Laboratories's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 2 | Johnson and Johnson | 681,032 | 49.36 % |
| 3 | Beone Medicines Ltd | 589,304 | 26.61 % |
| 4 | Abbvie Inc | 528,644 | 38.26 % |
| 5 | Merck and Co Inc | 375,021 | 81.05 % |
| 6 | Novartis Ag | 1,234 | 12.3% |
| 7 | Abbott Laboratories | 202,029 | -7.86 % |
| 8 | Novo Nordisk A | 1,234 | 12.3% |
| 9 | Pfizer Inc | 1,234 | 12.3% |
| 10 | Astrazeneca Plc | 1,234 | 12.3% |
| 11 | Vertex Pharmaceuticals Inc | 1,234 | 12.3% |
| 12 | Bristol myers Squibb Company | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Abbott Laboratories's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Abbott Laboratories's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 41.01 % | 37.53 % (avg) | +3.5 pp |
| Operating Margin | 15.77 % | industry median | +15.8 pp |
| EBITDA Margin | 23.21 % | -6.57 % (avg) | +29.8 pp |
| Capital Intensity (Capex / Revenue) | 4.47 % | 7.36 % (avg) | -2.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Abbott Laboratories's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 29.3x | 26.6x | +2.8x |
| EV / EBITDA | 16.2x | 15.9x | +0.3x |
| P/B | 3.1x | 4.3x | -1.2x |
| Return on Equity | 10.41 % | industry aggregate | -6.74 % |
| Return on Invested Capital | 5.39 % | -9.89 % (avg) | 15.28 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Abbott Laboratories's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 11.64 % | 4.34 % | 8.48 % | 24.47 % | 1.34 % | -8.12 % | 4.59 % | 5.67 % |
| Operating Margin | 11.94 % | 14.21 % | 15.48 % | 19.56 % | 19.16 % | 16.15 % | 16.27 % | 18.17 % |
| Return on Invested Capital | 4.02 % | 5.03 % | 5.95 % | 8.79 % | 8.63 % | 6.54 % | 6.48 % | 6.56 % |
| P/E | 53.0x | 41.8x | 44.0x | 33.1x | 27.4x | 30.6x | 15.1x | 34.1x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Abbott Laboratories's Strategic Group Map
Abbott Laboratories is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Abbott Laboratories's trailing-12-month revenue growth of 8.1% and operating margin of 15.8% compares with an average of 9.3% growth and 15.3% margin across its 8 closest peers by combined growth, margin and ROIC -- Abbott Laboratories sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Abbott Laboratories's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Abbott Laboratories falls in the Dog quadrant: relative market share of 0.16x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Abbott Laboratories's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.47 % vs industry average 7.36 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Abbott Laboratories's dedicated Suppliers and Customers pages, not here.
Abbott Laboratories's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Abbott Laboratories falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Abbott Laboratories's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 15.8 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+8.1% annualized vs trailing 12 months).
Weaknesses
- Return on equity 6.7 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.16x).
Opportunities
- A meaningful share of competitors (33.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Abbott Laboratories's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Sign in to see all peers for Abbott Laboratories.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Abbott Laboratories's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +8.6 % | +0.6 % |
Sign in to see all peers for Abbott Laboratories.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Abbott Laboratories's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Sign in to see all peers for Abbott Laboratories.
Abbott Laboratories's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
Sign in to see all peers for Abbott Laboratories.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Abbott Laboratories's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Abbott Laboratories | 37.27 | 4.34 |
| Eli Lilly And Company | 46.53 | 14.81 |
| Johnson and Johnson | 42.22 | 6.88 |
| Abbvie Inc | 51.38 | 8.01 |
| Merck and Co Inc | 122.44 | 5.63 |
| Novartis Ag | 22.92 | 5.66 |
| PEERS AVERAGE | 43.10 | 5.56 |
Sign in to see all peers for Abbott Laboratories.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.